India-based Biocon announced the publication of two peer-reviewed studies from the phase 3 INSIGHT program evaluating MYL-1701P, its aflibercept biosimilar approved by the FDA as Yesafili (aflibercept-jbvf), for the treatment of diabetic macular edema.1,2 The first study, published June 29, 2026, reported findings from a 20-week, multicenter, open-label extension study of participants with diabetic macular edema who completed the 52-week global phase 3 INSIGHT trial. The extension evaluated safety, efficacy, and immunogenicity in patients who either continued treatment with MYL-1701P or switched from reference aflibercept to MYL-1701P.1 According to Biocon, safety, efficacy, and immunogenicity profiles were comparable between the continuation and switch groups. Best corrected visual acuity, central subfield thickness, and ETDRS letter gains were maintained through the extension period in both treatment groups.
Filter by:
Eyewire News
Eyetube
Kevin J. Corcoran, COE, CPC, CPMA, FNAO
View More
New Retina Radio is a place to hear stories about retina that are told nowhere else.
The RETINAWS panel led by Kourous Rezaei, MD, discuss techniques for vitreoretinal surgery and rare surgical cases.
Eyewire headlines are now available as a weekly podcast! Listen Now
